These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 21138638)

  • 21. [Effects of acupuncture on body mass index and waist-hip ratio in the patient of simple obesity].
    He L; Gao XL; Deng HX; Zhao YX
    Zhongguo Zhen Jiu; 2008 Feb; 28(2):95-7. PubMed ID: 18405150
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of a 1-year dietary intervention with n-3 polyunsaturated fatty acid-enriched olive oil on non-alcoholic fatty liver disease patients: a preliminary study.
    Sofi F; Giangrandi I; Cesari F; Corsani I; Abbate R; Gensini GF; Casini A
    Int J Food Sci Nutr; 2010 Dec; 61(8):792-802. PubMed ID: 20465434
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effects of Yiqi Sanju Formula on non-alcoholic fatty liver disease: a randomized controlled trial].
    Lou SY; Liu Y; Ma YY; Chen HY; Chen WH; Ying J; He YM; Wang WJ
    Zhong Xi Yi Jie He Xue Bao; 2008 Aug; 6(8):793-8. PubMed ID: 18664346
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Measurement error and ethnic comparisons of measures of abdominal obesity.
    Dhaliwal SS; Welborn TA
    Prev Med; 2009; 49(2-3):148-52. PubMed ID: 19589354
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Distribution pattern of traditional Chinese medicine syndromes in 793 patients with fatty liver disease].
    Wei HF; Liu T; Xing LJ; Zheng PY; Ji G
    Zhong Xi Yi Jie He Xue Bao; 2009 May; 7(5):411-7. PubMed ID: 19435553
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatic unsaturated fatty acids in patients with non-alcoholic fatty liver disease assessed by 3.0T MR spectroscopy.
    van Werven JR; Schreuder TC; Nederveen AJ; Lavini C; Jansen PL; Stoker J
    Eur J Radiol; 2010 Aug; 75(2):e102-7. PubMed ID: 20116951
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Use of Legalon in non-alcoholic fatty liver disease].
    Buturova LI; Tsybizova TA; Kalinin AV
    Eksp Klin Gastroenterol; 2010; (5):69-75. PubMed ID: 20734480
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical and histological features of non-alcoholic fatty liver disease].
    Shi JP; Xun YH; Hu CB; Zhang L; Liu H; Lou GQ; Fan JG
    Zhonghua Gan Zang Bing Za Zhi; 2009 Nov; 17(11):812-6. PubMed ID: 19958638
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The association of cardiovascular risk factors with nonalcoholic fatty liver disease in health checkup examinees].
    Yu JH; Lee KS; Lee SY; Hong AR; Park YS
    J Prev Med Public Health; 2008 Nov; 41(6):407-12. PubMed ID: 19037170
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Depression, anxiety, and nonalcoholic steatohepatitis.
    Elwing JE; Lustman PJ; Wang HL; Clouse RE
    Psychosom Med; 2006; 68(4):563-9. PubMed ID: 16868265
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nonalcoholic fatty liver disease.
    Bayard M; Holt J; Boroughs E
    Am Fam Physician; 2006 Jun; 73(11):1961-8. PubMed ID: 16770927
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Taurine in the treatment of non-alcoholic fatty liver disease].
    Zvenigorodskaia LA; Ovsiannikova ON; Noskova KK; Nilova TV; Elizarova EP
    Eksp Klin Gastroenterol; 2010; (7):43-50. PubMed ID: 21033082
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Non-alcoholic hepatic steatosis: the role of policosanols in associated hyperlipidemia].
    Musto D; Martorelli L; Russo M; Esposito G; Amato MR; Esposito P; Riegler G
    Minerva Gastroenterol Dietol; 2010 Dec; 56(4):389-95. PubMed ID: 21139538
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment of fatty liver with essential phospholipids].
    Arendt R; Nowotny P; Teichmann W
    Z Gesamte Inn Med; 1970 Jul; 25(13):587-9. PubMed ID: 5523267
    [No Abstract]   [Full Text] [Related]  

  • 35. Fatty liver and liver transplantation.
    Koehler E; Watt K; Charlton M
    Clin Liver Dis; 2009 Nov; 13(4):621-30. PubMed ID: 19818309
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease.
    McPherson S; Stewart SF; Henderson E; Burt AD; Day CP
    Gut; 2010 Sep; 59(9):1265-9. PubMed ID: 20801772
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High prevalence of elevated liver enzymes in blood donors: associations with male gender and central adiposity.
    Papatheodoridis GV; Goulis J; Christodoulou D; Manolakopoulos S; Raptopoulou M; Andrioti E; Alexandropoulos N; Savvidou S; Papachristou A; Zervou E; Seferiadis K; Kousidou P; Vogiatzakis E; Tsianos E
    Eur J Gastroenterol Hepatol; 2007 Apr; 19(4):281-7. PubMed ID: 17353691
    [TBL] [Abstract][Full Text] [Related]  

  • 38. What is the best indicator for evaluating treatment response in nonalcoholic fatty liver disease: histology or aminotransferase levels?
    Akyuz F; Demir K; Cevikbas U; Okten A
    J Gastroenterol Hepatol; 2005 Jan; 20(1):167-8. PubMed ID: 15610470
    [No Abstract]   [Full Text] [Related]  

  • 39. A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease.
    Fernández-Miranda C; Pérez-Carreras M; Colina F; López-Alonso G; Vargas C; Solís-Herruzo JA
    Dig Liver Dis; 2008 Mar; 40(3):200-5. PubMed ID: 18261709
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
    Younossi ZM
    Aliment Pharmacol Ther; 2008 Jul; 28(1):2-12. PubMed ID: 18410557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.